Helix BioPharma Ratios and Metrics

Market cap in millions USD. Fiscal year is August - July.

Millions USD. Fiscal year is Aug - Jul.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Mar '26 Mar 5, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021	2020 - 2016
Market Capitalization	117	57	41	32	25	94	Upgrade
Market Cap Growth	304.41%	40.48%	27.81%	25.38%	-72.89%	75.26%	Upgrade
Enterprise Value	117	57	40	31	26	92	Upgrade
Last Close Price	1.73	0.60	0.83	0.72	0.77	3.58	Upgrade
PB Ratio	10.18	5.09	-626.39	-49.71	102.32	-84.09	Upgrade
P/TBV Ratio	-	-	-	-	102.32	-	Upgrade
Debt / Equity Ratio	0.02	0.02	-	-	7.74	-2.59	Upgrade
Net Debt / Equity Ratio	-0.01	0.02	12.01	0.96	-2.46	-0.03	Upgrade
Net Debt / EBITDA Ratio	0.03	-0.05	0.12	0.13	0.13	0.00	Upgrade
Net Debt / FCF Ratio	0.04	-0.07	0.21	0.15	0.12	0.00	Upgrade
Quick Ratio	0.18	0.06	0.72	0.46	1.03	1.01	Upgrade
Current Ratio	0.23	0.13	0.92	0.53	1.08	1.04	Upgrade
Return on Equity (ROE)	-66.34%	-67.18%	-	-	-	-1205.79%	Upgrade
Return on Assets (ROA)	-30.36%	-33.25%	-458.65%	-166.12%	-96.84%	-127.23%	Upgrade
Return on Capital Employed (ROCE)	-29.40%	-34.60%	10265.60%	748.60%	-1887.50%	-4780.60%	Upgrade
Earnings Yield	-2.98%	-6.56%	-16.43%	-14.97%	-20.11%	-6.86%	Upgrade
FCF Yield	-2.57%	-4.83%	-9.28%	-13.18%	-19.94%	-7.94%	Upgrade
Buyback Yield / Dilution	-35.46%	-25.29%	-15.11%	-29.26%	-8.41%	-7.97%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.